Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Semaglutide
Ozempic
Routinely available
SMC (SMC2092)
22/04/2019
Indication
Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. SMC restriction: In addition to other oral anti-diabetic medicines, or as an add-on to basal insulin, as an alternative glucagon-like peptide-1 receptor agonist option.
Therapeutic Area
Endocrine system
Status Description
Routinely available in line with national guidance
Formulation
0.25mg, 0.5mg and 1mg solution for injection in pre-filled pen
Comments
April 2019 - Routinely available in line with national guidance. Added to the LJF.